Pathogen inactivation treatment of triple‐dose apheresis platelets with amotosalen and ultraviolet a light

BACKGROUND: A triple storage (TS) set allows for pathogen inactivation (PI) treatment of triple‐dose apheresis platelet products with amotosalen + UVA. We evaluated the quality and metabolic parameters of platelet concentrates (PCs) pathogen inactivated and stored for 7 days. MATERIALS AND METHODS: Twelve triple‐dose products collected with two different apheresis platforms were treated with amotosalen+UVA. Products were split into three single‐dose units. Testing was made pretreatment, after splitting, at days 5 and 7 of storage. RESULTS: Single‐dose PI PCs had a mean platelet content of 2.89 ± 0.35 x 10(11). From baseline to day 7, pH remained stable (7.1 ± 0.1 vs. 7.0 ± 0.1), pO(2) increased (11.3 ± 2.4 vs. 18.3 ± 3.5 kPa) as did LDH (201 ± 119 vs. 324 ± 203 U/L) and lactate (3.6 ± 1.7 vs. 12.1 ± 1.5 mmol/L) (all p < 0.01); pCO(2) decreased (4.1 ± 0.8 vs. 1.5 ± 0.7 mmHg; p < 0.01) and so did bicarbonate (6.6 ± 1.1 vs. 2.5 ± 1.4 mmol/L), glucose (5.6 ± 1.2 vs. 0.4 ± 0.4 mmol/L) and ATP (3.4 ± 0.9 vs. 2.5 ± 1.4 nmol/10(8) platelets) (all p < 0.05). CONCLUSION: Triple‐dose PCs processed with the TS sets fulfilled the quality requirements and displayed metabolic changes of expected extent during 7‐day storage.